CurrentBlue Cross Blue Shield - IowaPolicy 05.04.72

Vtama (tapinarof) topical therapy coverage — medical necessity criteria

Defines medical necessity criteria, quantity limits, and continuation requirements for coverage of Vtama (tapinarof) cream for plaque psoriasis and atopic dermatitis for Wellmark members.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyVtama (tapinarof) topical therapy coverage — medical necessity criteria

Policy CodePolicy 05.04.72

Change TypeNo material changes

Effective DateMar 12, 2025

Next Review DateAug 1, 2025

Key ActionObtain prior authorization demonstrating indication, age criteria, prior treatment failures or intolerance, and adherence to quantity limits.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

60 gm/30dstandard quantity limit

120 gm/30dhigher quantity if needed

Adults & childrenage indications

6–12 moapproval duration

Coverage Criteria for Vtama (tapinarof)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy — Plaque Psoriasis

Covered when ALL of the following are met:

Plaque psoriasis initial: Requested drug prescribed for topical treatment of plaque psoriasis; patient is 18 years of age or older; patient has experienced inadequate response or intolerance to at least TWO specified prior therapies (unless all options are contraindicated).

Quantity allowance: If body surface area requires more than 60 grams per month, coverage for up to 120 grams per 30 days is allowed.>60 gm/month BSA requirement

Initial Therapy — Atopic Dermatitis

Covered when ALL of the following are met:

Atopic dermatitis initial: Requested drug prescribed for topical treatment of atopic dermatitis; patient is 2 years of age or older.

Prior therapy / intolerance: Patient has experienced inadequate treatment response, intolerance, or has a contraindication to required prior therapies (including scenarios such as intolerance to topical calcineurin inhibitors and corticosteroids for sensitive skin areas).

Quantity allowance: If body surface area requires more than 60 grams per month, coverage for up to 120 grams per 30 days is allowed.>60 gm/month BSA requirement

Continuation Therapy

Continuation covered when ALL of the following are met:

Positive clinical response: Patient has achieved or maintained a positive clinical response to therapy as evidenced by improvement in signs and symptoms from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain, erythema, edema, xerosis, erosions, excoriation, oozing/crusting, lichenification, pruritus).

Documentation of clinical improvement required.

Duration and quantity: Approvals for continuation: plaque psoriasis — 12 months with quantity limit not to exceed 60 gm per 30 days (coverage for 120 gm per 30 days when BSA requires >60 gm); atopic dermatitis — 12 months with same quantity limits.

Use of Vtama without required prior documentation or outside specified age or quantity limits is not permitted. Prior authorization must document the required prior treatment attempts or intolerance (for example, inadequate response or intolerance to at least two specified therapies) and, for continuation, evidence of clinical improvement or maintenance from baseline (e.g., reduction in erythema, edema, xerosis, erosion, excoriation, oozing/crusting, lichenification, or pruritus).

Requests that exceed the standard quantity limits (60 grams per 30 days) must include justification that the treated body surface area requires greater amounts; when >60 grams per month are clinically required, coverage may be provided up to 120 grams per 30 days. Lack of required prior therapy documentation, age/indication nonconformance, or missing clinical response documentation are grounds for denial.

Procedures, Codes, and Quantity Limits

Procedures and billing codesmixed

Policy refers generally to use of appropriate CPT, HCPCS, revenue, and ICD diagnostic codes; no specific codes listed.

Quantity limit — inv-07

Standard quantity limit60 grams per 30 days

BSA-based allowanceUp to 120 grams per 30 days when treating a body surface area that requires >60 grams per month

Approval duration (plaque psoriasis)12 months with quantity limit not to exceed 60 gm/30 days (120 gm allowed when BSA requires >60 gm)

Prior Authorization, Documentation, and Step Therapy

Prior Authorization

Prior Authorization Required

Prior authorization is required. Requests must document the indication (e.g., plaque psoriasis or atopic dermatitis), patient age criteria, prior treatment failures or intolerance, and planned quantity. Approval durations and quantity limits depend on indication and body surface area treated.

Prior authorization required for topical Vtama (tapinarof).
Indications must be specified (plaque psoriasis or atopic dermatitis).
Patient must meet age criteria: ≥ 18 years for plaque psoriasis.
Approval durations: 6 months for plaque psoriasis; 12 months for atopic dermatitis.
Quantity limits: 60 g per 30 days standard; up to 120 g per 30 days when body surface area requires >60 g/month.

Documentation Required

Required Clinical Documentation

Provide baseline clinical signs and symptoms and objective documentation of response for continuation requests. Evidence must show improvement or maintenance of response from baseline (for example: reduction in erythema, scaling, pruritus, edema, oozing/crusting, fissuring, lichenification, pain, or other relevant signs/symptoms).

Initial requests: diagnosis, patient age, and documentation of prior treatment failures/intolerance as required by indication.
Continuation requests: documentation of baseline signs/symptoms and evidence of clinical improvement or maintained benefit.
If therapy is being continued after sample or manufacturer assistance use, member must meet same initial criteria.

Step Therapy

Step Therapy / Prior Treatments

Step therapy and prior-treatment requirements must be documented: inadequate response or intolerance to specified prior therapies is required before approval.

Plaque psoriasis: inadequate response or intolerance to at least TWO specified prior topical therapies (unless contraindicated).
Atopic dermatitis: inadequate response, intolerance, or contraindication to a topical calcineurin inhibitor and to a medium-or-higher potency topical corticosteroid when required by the criteria.

Denial Risk

Denial Triggers / Quantity Limits

Requests exceeding quantity limits or lacking required documentation (diagnosis, age, prior-treatment history, baseline and follow-up response) are subject to denial.

Denial triggers include: missing prior authorization, absent documentation of prior treatment failures/intolerance, no baseline or follow-up clinical response for continuation, or requests above quantity limits without justification of body surface area.
Quantity limit: 60 g per 30 days standard; 120 g per 30 days requires documentation that body surface area necessitates >60 g/month.

Background on Tapinarof (Vtama)

Tapinarof (Vtama) cream 1% is a topical aryl hydrocarbon receptor agonist indicated for the treatment of plaque psoriasis in adults and for atopic dermatitis in patients aged 2 years and older. This policy aligns coverage with labeled indications and requires prior treatment attempts and documentation of clinical response for continuation.

For plaque psoriasis and atopic dermatitis, Vtama is considered when patients have had inadequate response or intolerance to prior therapies; continuation approvals require demonstration of a positive clinical response or maintained benefit from baseline. Standard approval durations and quantity limits apply — typically up to 60 grams per 30 days, with up to 120 grams per 30 days allowed when the treated body surface area necessitates greater use.

Definitions and Key Terms

Vtama (tapinarof) cream 1% — inv-13

DrugVtama (tapinarof) cream, 1%

MechanismAryl hydrocarbon receptor agonist (topical)

IndicationsTopical treatment of plaque psoriasis in adults; topical treatment of atopic dermatitis in patients aged ≥2 years

Quantity limits — inv-14

Definition — standard limitStandard coverage up to 60 grams per 30 days

Definition — BSA-based limitWhen body surface area requires more than 60 grams per month, coverage may be provided up to 120 grams per 30 days

ApplicationQuantity limits apply to initial and continuation approvals; plaque psoriasis continuation approvals noted for 12 months with these limits